Advanced search
Publication Cover
Current Eye Research Volume 36, 2011 - Issue 9
Submit an article Journal homepage
256
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Diurnal Intraocular Pressure Efficacy of the Timolol-Brimonidine Fixed Combination and the Timolol-Dorzolamide Fixed Combination as a First Choice Therapy in Patients with Pseudoexfoliation Glaucoma

Nurşen YükselOphthalmology Department, Medical School, Kocaeli University, Kocaeli, TurkeyCorrespondence[email protected]
,
Mustafa GökOphthalmology Department, Medical School, Kocaeli University, Kocaeli, Turkey
,
Özgül AltıntaşOphthalmology Department, Medical School, Kocaeli University, Kocaeli, Turkey
&
Yusuf ÇağlarOphthalmology Department, Medical School, Kocaeli University, Kocaeli, Turkey
Pages 804-808 | Received 17 Sep 2010, Accepted 21 Apr 2011, Published online: 18 Aug 2011

REFERENCES

  • Schlötzer-Schrehardt U, Naumann GO. Ocular and systemic pseudoexfoliation syndrome. Am J Ophthalmol. 2006;141(5):921–937.
  • Ritch, R., Schlötzer-Schrehardt, U. Exfoliation syndrome. Surv Ophthalmol. 2001;45:265–315.
  • Ritch R, Schlötzer-Schrehardt U, Konstas AGP. Why is glaucoma associated with exfoliation syndrome? Prog Retin Eye Res. 2003;22:253–275.
  • Konstas AGP, Stewart WC, Stroman GA. Clinical presentation and initial treatment patterns in patients with exfoliation glaucoma versus primary open angle glaucoma. Ophthal Surg Lasers. 1997;28:111–117
  • Konstas AG, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open angle glaucoma. Arch Ophthalmol. 1997;115:182–185.
  • Konstas AGP, Tsironi S, Ritch R. Update on the pathogenesis and management of exfoliation syndrome and exfoliative glaucoma. Compr Ophthalmol Update. 2006;7:131–141
  • Ritch R. The management of exfoliative glaucoma. Prog Brain Res. 2008;173:211–224
  • Cox JA, Mollan SP, Bankart J, et al. Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: A systematic review. Br J Ophthalmol. 2008;92:729–734.
  • Hatanaka M, Grigera DE, Barbosa WL, et al. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. J Glaucoma. 2008;17:674–679
  • Arcieri ES, Arcieri RS, Pereira AC, et al. Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamidetimolol in patients with elevated intraocular pressure. Curr Med Res Opin. 2007;23:683–689.
  • Konstas AGP, Kozobolis VP, Tersis I, et al. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye. 2003;17:41–46.
  • Parmaksiz S, Yüksel N, Karabas VL, Ozkan B, Demirci G, Caglar Y. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006;16(1):73–80.
  • Garcia- Feijoo, Saenz-Frances F, Maria Martinez-de-la-Casa J, et al. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol. Curr Med Res Opin. 2010;26:1599–1606.
  • Nixon DR, Yan DB, Chartrand JP, et al. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin. 2009;25(7):1645–1653.
  • Konstas AGP, Hollo G, Astakhov Y, et al. Factors associated with long-term progression or stability in exfoliation glaucoma. Arch Ophthalmol. 2004;122:29–33.
  • Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: A 12-month randomized trial. Arch Ophthalmol. 2006;124:1230–1238.
  • Williams GC, Orengo-Nania S, Gross RL. Incidence of brimonidine allergy in patients previously allergic to apraclonidine. J Glaucoma. 2000;9:235–238.
  • Alvarado JA. Reduced ocular allergy with fixed-combination 0.2% brimonidine-0.5% timolol. Arch Ophthalmol. 2007;125(5):717.
  • Motolko MA. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr Med Res Opin. 2008;24(9):2663–2667.
  • Liu JHK PhD, Medeiros FA, Rigby Slight, Weinreb RN. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology. 2010;117:2075–2079.
  • Konstas AG, Stewart WC, Topouzis F, et al. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol. 2001;131:729–733.
  • Quaranta L, Gandolfo F, Rovida F, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47:2917–2923.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.